Liposomal Amphotericin B as Monotherapy in Relapsed Coccidioidal Meningitis

Stewart, Ethan R.; Eldridge, Matthew L.; Mchardy, Ian Howard; Cohen, Stuart H.; Thompson, George R.

doi:10.1007/s11046-017-0240-7

Cited by 17 publications

(12 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Coccidioidal meningitis can also be treated by a similar liposomal formulation encapsulating amphotericin B and demonstrated lower nephrotoxicity and higher concentrations in the reticuloendothelial system as compared to free amphotericin B. The clinical study in the hospital setting proved a potential treatment option in patients with chronic meningitis and undertaking triazole therapy [16]. Similarly, another clinical study reported that administration of low-dose amphotericin B liposomes in combination with voriconazole was effective in C. neoformans meningitis.…”

Section: Lipid-based Nanocarriersmentioning

confidence: 99%

Progress in the Application of Nanoparticles and Graphene as Drug Carriers and on the Diagnosis of Brain Infections

et al. 2021

View full text Add to dashboard Cite

The blood–brain barrier (BBB) is the protective sheath around the brain that protects the sensitive microenvironments of the brain. However, certain pathogens, viruses, and bacteria disrupt the endothelial barrier and cause infection and hence inflammation in meninges. Macromolecular therapeutics are unable to cross the tight junctions, thereby limiting their bioavailability in the brain. Recently, nanotechnology has brought a revolution in the field of drug delivery in brain infections. The nanostructures have high targeting accuracy and specificity to the receptors in the case of active targeting, which have made them the ideal cargoes to permeate across the BBB. In addition, nanomaterials with biomimetic functions have been introduced to efficiently cross the BBB to be engulfed by the pathogens. This review focuses on the nanotechnology-based drug delivery approaches for exploration in brain infections, including meningitis. Viruses, bacteria, fungi, or, rarely, protozoa or parasites may be the cause of brain infections. Moreover, inflammation of the meninges, called meningitis, is presently diagnosed using laboratory and imaging tests. Despite attempts to improve diagnostic instruments for brain infections and meningitis, due to its complicated and multidimensional nature and lack of successful diagnosis, meningitis appears almost untreatable. Potential for overcoming the difficulties and limitations related to conventional diagnostics has been shown by nanoparticles (NPs). Nanomedicine now offers new methods and perspectives to improve our knowledge of meningitis and can potentially give meningitis patients new hope. Here, we review traditional diagnosis tools and key nanoparticles (Au-NPs, graphene, carbon nanotubes (CNTs), QDs, etc.) for early diagnosis of brain infections and meningitis.

show abstract

Section: Lipid-based Nanocarriersmentioning

confidence: 99%

Progress in the Application of Nanoparticles and Graphene as Drug Carriers and on the Diagnosis of Brain Infections

et al. 2021

View full text Add to dashboard Cite

show abstract

“…In vivo (human) Stewart et al, 2018 H. capsulatum In vivo (human) Johnson et al, 2002 Lipid complex (Abelcet) AmB C. immitis In vivo (human) Koehler et al, 1998;Sidhu et al, 2018 C. posadasii In vivo (rabbits) Capilla et al, 2007;Clemons et al, 2009 PLGA-DMSA AmB P. brasiliensis In vivo (mice) Amaral et al, 2009; abnormalities compared to the AmB deoxycholate treated group. In addition, the formulation raised no genotoxic and cytotoxic effects (Amaral et al, 2009).…”

Section: Aspergillosismentioning

confidence: 99%

“…AmBisome® is effective in treating coccidioidomycosis in human patients (Stewart et al, 2018 ). During treatment of coccidioidal meningitis for a period of 9 months, AmBisome® did not present clinical or laboratory data suggestive of toxicity (Rangel et al, 2010 ).…”

Section: Current Scenario Of Nanotechnology In the Treatment And Vaccmentioning

confidence: 99%

Therapies and Vaccines Based on Nanoparticles for the Treatment of Systemic Fungal Infections

Kischkel

Rossi

Santos

et al. 2020

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

Treatment modalities for systemic mycoses are still limited. Currently, the main antifungal therapeutics include polyenes, azoles, and echinocandins. However, even in the setting of appropriate administration of antifungals, mortality rates remain unacceptably high. Moreover, antifungal therapy is expensive, treatment periods can range from weeks to years, and toxicity is also a serious concern. In recent years, the increased number of immunocompromised individuals has contributed to the high global incidence of systemic fungal infections. Given the high morbidity and mortality rates, the complexity of treatment strategies, drug toxicity, and the worldwide burden of disease, there is a need for new and efficient therapeutic means to combat invasive mycoses. One promising avenue that is actively being pursued is nanotechnology, to develop new antifungal therapies and efficient vaccines, since it allows for a targeted delivery of drugs and antigens, which can reduce toxicity and treatment costs. The goal of this review is to discuss studies using nanoparticles to develop new therapeutic options, including vaccination methods, to combat systemic mycoses caused by Candida sp., Cryptococcus sp., Paracoccidioides sp., Histoplasma sp., Coccidioides sp., and Aspergillus sp., in addition to providing important information on the use of different types of nanoparticles, nanocarriers and their corresponding mechanisms of action.

show abstract

“…The deadliest infections include meningitis or the dissemination to the central nervous system and it is recommended that these cases are given lifelong antifungal medication [142]. Studies investigating the effects of ceasing azole therapy for C. immitis have further demonstrated that with any level of infection, long-term azole or triazole therapy is suggested to prevent relapse that could lead to a more serious Coccidioides infection, especially if one is immunocompromised [143].…”

Section: Antifungal Drugs/treatmentmentioning

confidence: 99%

The mysterious desert dwellers:Coccidioides immitis and Coccidioides posadasii, causative fungal agents of coccidioidomycosis

2019

View full text Add to dashboard Cite

The genus Coccidioides consists of two species: C. immitis and C. posadasii . Prior to 2000, all disease was thought to be caused by a single species, C. immitis . The organism grows in arid to semiarid alkaline soils throughout western North America and into Central and South America. Regions in the United States, with highest prevalence of disease, include California, Arizona, and Texas. The Mexican states of Baja California, Coahuila, Sonora, and Neuvo Leon currently have the highest skin test positive results. Central America contains isolated endemic areas in Guatemala and Honduras. South America has isolated regions of high endemicity including areas of Colombia, Venezuela, Argentina, Paraguay, and Brazil. Although approximately 15,000 cases per year are reported in the United States, actual disease burden is estimated to be in the hundreds of thousands, as only California and Arizona have dedicated public health outreach, and report and track disease reliably. In this review, we survey genomics, epidemiology, ecology, and summarize aspects of disease, diagnosis, prevention, and treatment.

show abstract

Liposomal Amphotericin B as Monotherapy in Relapsed Coccidioidal Meningitis

Cited by 17 publications

References 13 publications

Progress in the Application of Nanoparticles and Graphene as Drug Carriers and on the Diagnosis of Brain Infections

Progress in the Application of Nanoparticles and Graphene as Drug Carriers and on the Diagnosis of Brain Infections

Therapies and Vaccines Based on Nanoparticles for the Treatment of Systemic Fungal Infections

The mysterious desert dwellers:Coccidioides immitis and Coccidioides posadasii, causative fungal agents of coccidioidomycosis

Contact Info

Product

Resources

About